Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06315595 · ClinicalTrials.gov registry record
Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI
A clinical trial of Prostate Neoplasm, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 2
- Study locations
NCT06315595 is a study of Prostate Neoplasm that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 1,000 participants, roughly in line with the 1,019-participant average among 9 other Prostate Neoplasm trials with a reported enrollment target. The trial reports 2 study locations across 2 states.
The verdict
NCT06315595, a study of Prostate Neoplasm, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study evaluates if technical improvements in MRI can be used to provide improved performance contrast-enhanced MRI as used for angiography and perfusion as well as in non-contrast MRI.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (2)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2015-09-30 |
| Est. Completion | 2030-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06315595
The ClinicalTrials.gov registry entry for NCT06315595 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,019-participant average among 9 other Prostate Neoplasm trials with a reported enrollment target. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06315595 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06315595 about?
NCT06315595 is a clinical study titled "Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI". This study evaluates if technical improvements in MRI can be used to provide improved performance contrast-enhanced MRI as used for angiography and perfusion as well as in non-contrast MRI.
What is the current status of trial NCT06315595?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2015-09-30. Estimated completion is 2030-09-30.
What conditions does trial NCT06315595 study?
This clinical trial studies the following conditions: Prostate Neoplasm.
What interventions are being tested in trial NCT06315595?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06315595?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06315595 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
RECRUITING · NA
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
RECRUITING
-
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
RECRUITING · Phase 2
-
Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy
RECRUITING · Phase 1
-
Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.